| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 8th January 2021 | Advisors Llc Perceptive | 347,332 | Open or private purchase | $9.21 | $3,198,927.72 |
| 8th January 2021 | Advisors Llc Perceptive | 152,668 | Open or private purchase | $10.21 | $1,558,740.28 |
| 8th January 2021 | Advisors Llc Perceptive | 50,000 | Open or private purchase | $7.60 | $380,000.00 |
| 7th January 2021 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $8.13 | $4,065,000.00 |
| 23rd November 2020 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $12.85 | $6,425,000.00 |
| 17th November 2020 | Martha J Demski | 7,042 | Exercise of derivative | $2.35 | $16,548.70 |
| 17th November 2020 | Martha J Demski | 7,042 | Bona fide gift | $0.00 | |
| 17th November 2020 | Martha J Demski | 7,042 | Bona fide gift | $0.00 | |
| 27th October 2020 | Advisors Llc Perceptive | 3,000,000 | Open or private purchase | $10.00 | $30,000,000.00 |
| 21st October 2020 | Advisors Llc Perceptive | 43,195 | Open or private purchase | $10.09 | $435,837.55 |
Adma Biologics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center and Corporate.
Ticker: ADMA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1368514
Employees: 318
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Common Stock, Shares, Issued: $86 M (45%)
News
ADMA Biologics: A Perfect Storm
5th January 2021
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
16th December 2020